Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study
Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact t...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , , , , , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| মালা: | Asian Journal of Andrology |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=545;epage=550;aulast=Zhao |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|